|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GERMANTOWN, Md. – Sept. 10, 2019 – PRLog — Primetime Life Sciences, LLC, a Maryland based pharmaceutical company focused on discovery and development of new and smart treatments, announced today that the company has successfully met the Phase I grant milestones, and has been awarded Phase II funding of $2.63 million from a Fast Track Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health (NIMH). The SBIR program supports scientific excellence and technological innovation by encouraging small businesses to engage in translation research and bring innovative treatments.
Alex Trebek appeared well en route to surviving pancreatic cancer this past summer when his doctors followed up his initial successful chemotherapy with an undisclosed immunotherapy. That move backfired.
“I was doing so well. And my numbers went down to the equivalent of a normal human being who does not have pancreatic cancer. So we were all very optimistic. And they said, ‘Good, we’re gonna stop chemo, we’ll start you on immunotherapy,” Trebek said September 17 on ABC’s Good Morning America. “I lost about 12 pounds in a week. And my numbers went sky-high, much higher than they were when I was first diagnosed.”
A pair of Baltimore teams focused on medication use are joining forces in the quest to ensure patients follow their prescribed plans.
Tech company emocha Mobile Health and the Baltimore-based University of Maryland School of Pharmacy’s Center for Innovative Pharmacy Solutions are collaborating to offer a medication review that combines pharmacists and a mobile app. This will be offered as emocha expands to hospitals, health systems and health insurers, said CEO Sebastian Seigeur.
“This is now our standard,” he said.
Image: Telehealth at the University of Maryland School of Pharmacy’s eHealth Center. (Courtesy photo)
NextGen Venture Partners reported Tuesday that it raised more than $42 million for its second fund, nearly double its initial haul three years ago.
The $42.68 million in new funding comes about a year after the venture firm first indicated plans to raise a fund, according to a Securities and Exchange Commission filing. Though, those efforts were delayed by its acquisition in early 2018 by Baltimore investment giant Brown Advisory. While Tuesday’s filing lists Brown Advisory CEO Michael Hankin as the top executive, NextGen co-founders Dan Mindus and Brett Gibson both remain managing partners, per the website, and still work in the D.C. area, according to their LinkedIn profiles.
As of yesterday, the XBI biotech index has not only reversed last month’s slump but reached the full-year high it set in April. And that’s despite the fact that drug pricing rhetoric has hardly subsided, and next year’s presidential election remains as unpredictable as ever.
Image: https://mailchi.mp
Venture capital has something of a reputation as a boys’ club, but there are women making their mark in this field. In particular, five women have been singled out for their contributions to the life sciences industry.
Bio Buzz selected five women venture capitalists who are considered “trailblazing investors shaping the future of life science investing” in the BioCapital Hotbed Community, which includes Delaware, Maryland, Virginia and Washington, D.C.
A consortium of leaders from Boston’s biggest research institutions are joining forces on advancing biological manufacturing and innovation.
Executives from Harvard University, the Massachusetts Institute of Technology, Fujifilm Diosynth Biotechnologies, GE Healthcare Life Sciences and Alexandria Real Estate Equities will serve as the board of directors of a planned $50M center of advanced biological innovation and manufacturing, the group announced Monday.
Image: Wikimedia Commons/Joseph Williams Harvard University’s Widener Library